**Earnings Conference Call Summary for Third Quarter: Key Financial Metrics**

**Diluted EPS (Earnings Per Share):**
- GAAP diluted EPS for Q3: $1.20
- Non-GAAP diluted EPS for Q3: $1.53
- Both figures show an increase from the previous year, with GAAP EPS up 3% and non-GAAP EPS up 7%.

**Effective Tax Rate:**
- Both GAAP and Non-GAAP effective tax rates decreased significantly by approximately 4.5% as compared to the prior year, positively impacting net income.

**Revenue:**
- Total company revenue grew by 4% year-over-year to $31.8 billion.

**Margins:**
- Consolidated GAAP and non-GAAP gross margin dollars increased by 2% and 1%, respectively.
- Gross margin rates decreased (GAAP down 8 basis points; Non-GAAP down 15 basis points), primarily due to pressures from generic pharmaceutical pricing.

**Operating Earnings:**
- Both GAAP and non-GAAP operating earnings declined by 8% and 4% respectively compared to the prior year, indicating some challenges in operational efficiency and/or cost increases.

**SG&A Expenses:**
- SG&A expenses increased by 5% year-over-year, primarily due to costs associated with pharma IT system upgrades, new Medical segment business wins, and infrastructure expenses related to Cordis.

**Cash Flow and Liquidity:**
- Net operating cash outflows were $198 million for the quarter.
- Cash and short-term investments stood at $1.6 billion.
- Significant cash generation is expected in the upcoming fourth quarter.

**Segment Performance:**
- **Pharmaceutical Segment:** Revenue grew by 3% to $28.4 billion, driven by the Specialty Solutions business and pharmaceutical distribution customers. However, segment profit decreased by 7% to $611 million due to generic pricing pressures and investments in the pharmaceutical IT platform.
- **Medical Segment:** Revenues increased by 9% to $3.4 billion, with a 16% profit increase to $148 million. The growth predominantly came from new and existing customer contributions. 

**Share Repurchase:**
- No shares were repurchased during the quarter, with $443 million remaining under the board-authorized share repurchase program.

**Forward Guidance:**
- Revenue growth for FY 2017 revised to mid to high single-digit percentages from previous higher estimates.
- Full-year non-GAAP EPS expected at the lower end of the $5.35 to $5.50 range, likely impacted by generic market pricing and other factors.
- The company remains disciplined in its expense management and investment to stimulate future growth.